Marina Biotech, Inc. is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. The Company's pipeline is orphan disease focused and includes a clinical program in Familial Adenomatous Polyposis (FAP) and preclinical programs in type 1 myotonic dystrophy (DM1) and Duchenne's muscular dystrophy (DMD). Its partners, ProNAi Therapeutics, Inc. (ProNAi) and Mirna Therapeutics, Inc. (Mirna) are focused on oncology and have clinical programs in recurrent or refractory non-Hodgkin's lymphoma and unresectable primary liver cancer or solid cancers with liver involvement, respectively. The Company has two liposomal-based delivery platforms. The first platform, SMARTICLES, defines a class of liposomes that are charge-reversible particles allowing delivery of active substance. The second platform utilizes amino-based liposomal delivery technology.